Faron Pharmaceuticals Oy · LSE:FARN
Faron Pharmaceuticals Oy — Corporate Update (October 2023)
15 slides from Faron Pharmaceuticals Oy's corporate update, Oct 11, 2023
Slide 1: Faron Pharmaceuticals BEXMAB study update
A CLEVER Approach to Fight Cancer Faron Pharmaceuticals BEXMAB study update October 11, 2023 London AIM: FARN Helsinki First North: FARON Faron Pharmaceuticals | Non-Confidential Information
Slide 2: Corporate Disclaimer
Corporate Disclaimer The contents of this presentation have not been approved by an authorized person within the meaning of Section 21 of the Financial Services and Markets Act 2000 (as amended) ("FSMA"). Reliance on the contents of this presentation for the purpose of engaging in any investment act
Slide 3: Harnessing the Power of Macrophages to Conquer Immune Resistance
Harnessing the Power of Macrophages to Conquer Immune Resistance CLEVER approach to sensitizing cancers to standard of care Bexmarilimab is a humanized monoclonal antibody to Clever-1 and primes the immune system to attack tumors Clever-1 is an immunosuppressive receptor on macrophages allowing tumo
Slide 4: Bexmarilimab's Therapeutic Potential in AML and MDS
Bexmarilimab's Therapeutic Potential in AML and MDS Dual mode of action: immune activation & reduced viability of leukemic cells o Bexmarilimab converts immuno- suppressive macrophages (innate imm- unity) to immune activators both in circulation and bone marrow o Direct binding of bexmarilimab block
Slide 5: Increase of Antigen Presentation and T Cell Activity in Leukemia Patients
Increase of Antigen Presentation and T Cell Activity in Leukemia Patients Bexmarilimab treatment results in immune activation in BM at tested dose levels (data as of October 5, 2023) Dose-dependent upregulation of antigen-presentation Increase of T cell numbers in the bone marrow of patients molecul
Slide 6: BEXMAB Phase 1/2 Study Evaluating Bexmarilimab with SoC
BEXMAB Phase 1/2 Study Evaluating Bexmarilimab with SoC Enrichment cohorts of DOUBLET now recruited Dose Finding (Phase 1) Efficacy Evaluation (Phase 2) POPULATION DOUBLET MDS MDS Phase 2 azacitidine + doses r/r AML r/r AML bexmarilimab MDS failed HMA based therapy MDS HMA failure POPULATION TRIPLET
Slide 7: Reduction of Bone Marrow Blasts in Majority of Patients
Reduction of Bone Marrow Blasts in Majority of Patients BEXMAB doublet cohorts, data as of October 5, 2023 Best % change BM blasts Patient 7 FARON PHARMACEUTICALS | NON-CONFIDENTIAL INFORMATION
Slide 8: Long Term Remission Observed Across Indications and Dose Levels
Long Term Remission Observed Across Indications and Dose Levels BEXMAB doublet cohorts, data as of October 5, 2023 Allo-HSCT mOS ~4 months for MDS HMA-failed mOS ~9 months for r/r AML HI-P: hematologic improvement platelets HI-N: hematologic improvement neutrophils HR: hematologic relapse 8 FARON PH
Slide 9: Responses Observed in Patients with MDS after HMA failure
Responses Observed in Patients with MDS after HMA failure BEXMAB doublet patients, data as of October 5, 2023 Allo-HSCT Blood recovery mOS ~4 months for MDS HMA-failed HI-N: hematologic improvement neutrophils 9 FARON PHARMACEUTICALS | NON-CONFIDENTIAL INFORMATION NE: non evaluable
Slide 10: Bexmarilimab Combination with Azacitidine Well-Tolerated
Bexmarilimab Combination with Azacitidine Well-Tolerated BEXMAB doublet (data as of October 5, 2023) Doublet cohorts (1, 3, 6 mg/kg Q1W) n=28) Treatment-Related Treatment-Related Adverse Events Grade 1+2 Grade ≥ 3 # AEs (%) n=229 Adverse Events Fever 4 (2) 0 (0) Any grade 18 (8) Constipation 2
Slide 11: Encouraging Data in Patients with High Unmet Medical Need
Encouraging Data in Patients with High Unmet Medical Need Conclusions of BEXMAB (October 5, 2023) AML and MDS remain diseases of unmet medical need, especially in relapsed settings Bexmarilimab is well-tolerated in combination with standards of care azacitidine Encouraging and durable responses obse
Slide 12: Independent Third-Party Evaluation of Current Clinical Burden
Independent Third-Party Evaluation of Current Clinical Burden Despite the high failure rate of R/R AML & MDS treatment, it could cost up to $million per patient Target Patient Population Relapse and refractory (r/r) acute myeloid leukaemia (AML) patients and hypomethylating agent (HMA) failed myelod
Slide 13: Visualizing Unmet Patient Need in High Risk MDS
Visualizing Unmet Patient Need in High Risk MDS Dismal outcome remains in 2023 for patients that will not receive stem cell transplant Transplants Adaptive Adverse Resistance; 44,3% event/non compliance; 15,0% CR, PR, or SD with HI; 20,3% Planned HSCT; SD without HI/PD; 5,0% 35,40% “The monumental l
Slide 14: Outlook for the Next 12 Months
Outlook for the Next 12 Months Clinical development Corporate BEXMAB Q4-2023 Completion of dose escalation and readout of enrichment cohorts Q4-2023 Dose selection for Phase 2 Q4-2023 Phase 2 initiation Regulatory interactions for additional designations & advice leading to Continue to build US team
Slide 15: Thank You
Thank You
Faron Pharmaceuticals Oy — Corporate Update (October 2023) on 6ix